[68]Ga-HA-DOTATATE Imaging for Neuroendocrine Tumors

Recruiting in Palo Alto (17 mi)

Overseen by Todd PW McMullen, MD, PhD, FRCSC, FACS

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: AHS Cancer Control Alberta

Disqualifiers: Pregnancy, Severe arthritis, Claustrophobia, others

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests a new type of body scan for patients with certain types of tumors. The scan uses a small amount of radioactive material to highlight tumors by sticking to specific spots on them. It aims to show that this method is safe and more accurate than current scans. The new scan is useful for locating primary tumors in patients with certain types of cancer.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the treatment [68]Ga-HA-DOTATATE for neuroendocrine tumors?

The research shows that 68Ga-DOTATATE PET/CT is a preferred imaging method for diagnosing and managing neuroendocrine tumors, helping doctors make better treatment decisions and improving patient outcomes. ^{1 2 3 4 5}

Is [68]Ga-HA-DOTATATE safe for use in humans?

The available research on [68]Ga-DOTATATE, a similar compound, suggests it is generally safe for use in imaging neuroendocrine tumors. It is widely used for diagnosing and managing these tumors, and no significant safety concerns have been reported in the studies reviewed. ^{2 6 7 8 9}

How does 68Ga-HA-DOTATATE imaging differ from other treatments for neuroendocrine tumors?

68Ga-HA-DOTATATE imaging is unique because it uses a special type of scan to detect neuroendocrine tumors by targeting somatostatin receptors, which are often present on these tumors. This method is more sensitive and accurate in identifying tumor locations compared to older imaging techniques like Octreoscan and MRI, making it a valuable tool for better diagnosis and management of these tumors. ^{1 3 5 10 11}

Research Team

Todd PW McMullen, MD, PhD, FRCSC, FACS

Principal Investigator

Associate Professor of Surgery and Oncology; Director, Division of Surgical Oncology, Department of Oncology

Eligibility Criteria

This trial is for individuals at least 14 years old with suspected or known tumors that have somatostatin receptors, such as various types of neuroendocrine tumors. Participants must be able to follow the study's protocol and have an ECOG score ≤ 3, indicating they are capable of self-care. They cannot join if they exceed the weight limit for PET scans, are pregnant, allergic to DOTATATE/somatostatin analogues, or unable to remain still during imaging.

Inclusion Criteria

I have recent evidence or tests suggesting I might have a neuroendocrine tumor (NET).

A standard CT or MRI obtained within 6 months of enrolment is required

I am 14 years old or older.

Exclusion Criteria

I am allergic to DOTATATE or similar drugs.

Weight exceeding the PET/CT or PET/MR scanner limit

I cannot stay still for long periods due to a condition like severe arthritis.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Safety Evaluation

Participants undergo [68]Ga-HA-DOTATATE PET/CT or PET/MRI scans to evaluate uptake by somatostatin receptor positive tumours. Safety evaluation includes vital signs, haematology, serum biochemistry, and adverse event assessment.

Up to 2 hours per scan

Up to 7 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging, with follow-up scans evaluated for abnormal accumulation of [68]Ga-HA-DOTATATE.

Up to 6 years

Treatment Details

Interventions

• [68]Ga-HA-DOTATATE (Radiopharmaceutical)

Trial Overview [68]Ga-HA-DOTATATE is being tested in this trial. It's a new diagnostic agent used in PET/CT or PET/MRI scans to detect somatostatin receptors on tumors more accurately than current methods like Octreoscan™. The study aims to ensure it's safe and effective for identifying these types of tumors.

Participant Groups

Group I: [68]Ga-HA-DOTATATE Experimental Treatment 1 Intervention

All participants will be imaged with \[68\]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven \[68\]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.

Who Is Running the Clinical Trial?

AHS Cancer Control Alberta

Lead Sponsor

Trials

188

Recruited

26,900+

Dr. Peter Jamieson

AHS Cancer Control Alberta

Chief Medical Officer since 2024

MD from the University of Alberta

Andre Tremblay

AHS Cancer Control Alberta

Chief Executive Officer

BA in Political Science from the University of Victoria, MA in Political Science from the University of British Columbia

Findings from Research

In a study of 81 patients with neuroendocrine tumors (NETs), Ga-68 DOTATATE PET/CT was more effective than F-18 FDG PET/CT in detecting positive scans in patients with low and intermediate-grade tumors, with 82.1% of DOTATATE scans positive compared to 54.5% for FDG (P = 0.04).

For high-grade, poorly-differentiated NETs, both DOTATATE and FDG PET/CT scans were equally effective, with all patients showing positive results, indicating that while DOTATATE is superior for lower-grade tumors, it does not provide additional benefits for high-grade tumors compared to FDG.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You, H., Kandathil, A., Beg, M., et al.[2021]

The validation of Ga-68-DOTA-Tyr3-octreotate (DOTATATE) production showed that it meets all European Pharmacopoeia quality control standards, with radiochemical purity consistently above 99% across three production runs.

The successful validation process ensures that Ga-68-DOTATATE is a reliable and safe radiopharmaceutical for neuroendocrine tumor imaging, demonstrating reproducibility in quality and efficacy for clinical use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis. Sammartano, A., Migliari, S., Scarlattei, M., et al.[2022]

Gallium-68 DOTA-Tyr-octreotatate (Ga-DOTATATE) PET/CT imaging is highly effective for managing neuroendocrine tumors, leading to a change in treatment for about 75% of patients compared to traditional imaging methods.

Ga-DOTATATE PET/CT is particularly useful for identifying well-differentiated tumors that express somatostatin receptors, while dedifferentiated tumors may require F FDG PET/CT for detection, highlighting the complementary nature of these imaging techniques.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Subramaniam, RM., Bradshaw, ML., Lewis, K., et al.[2019]

Dynamic 68Ga-DOTATATE PET-CT scans in 7 patients with localized pancreatic neuroendocrine tumors (pNETs) showed that the tumors had significantly higher uptake values (SUVmax and SUVmean) compared to normal pancreatic tissue, indicating effective tumor visualization.

The study found that the net influx rate (Ki) of pNETs was also significantly higher than that of normal tissue, suggesting that Ki may be a more reliable measure for evaluating treatment effects than standardized uptake values (SUV).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dynamic 68Ga-DOTA0-Tyr3-octreotate positron emission tomography-computed tomography for the evaluation of pancreatic neuroendocrine tumors: a pilot study. Yin, H., Liu, G., Tan, H., et al.[2023]

References

1. United States pubmed.ncbi.nlm.nih.gov

The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. [2021]

5. Australia pubmed.ncbi.nlm.nih.gov

High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. [2022]

6. India pubmed.ncbi.nlm.nih.gov

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. [2019]

8. United States pubmed.ncbi.nlm.nih.gov

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. [2022]

9. China pubmed.ncbi.nlm.nih.gov

Dynamic 68Ga-DOTA0-Tyr3-octreotate positron emission tomography-computed tomography for the evaluation of pancreatic neuroendocrine tumors: a pilot study. [2023]

10. Germany pubmed.ncbi.nlm.nih.gov

Early experience with (68)Ga-DOTATATE preparation. [2015]

11. United States pubmed.ncbi.nlm.nih.gov

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. [2022]